The city of Taizhou has made every effort to pool the wisdom of overseas talents so as to comprehensively promote the new practice of Chinese path to modernization in Taizhou.
Taizhou China Pharmaceutical High-tech Park is accelerating the construction of a 500-million-yuan nutrition and health food intelligent manufacturing project invested by Feng’ao Company so as to ensure its production by the end of this year.
By adopting the most advanced international technology to produce propolis soft capsules, this project is expected to achieve an annual output value of over 500 million yuan.
The CEO of this enterprise is Zhang Yong, a native of Jiangsu, who started a business in other provinces a long time ago. When attending the second Jiangsu Development Conference, he was extremely excited by the booming development momentum of his hometown. The following year, he relocated multiple production lines from other places back to his hometown of Taizhou.
“I chose to return to Taizhou to start my own business. Firstly, it is based on my hometown complex; secondly, Taizhou Pharmaceutical High-tech Zone is a national level pharmaceutical high-tech zone with complete industrial support and a good business environment. My goal is to strive to build an internationally advanced and domestically leading national level demonstration base for producing high-quality bee products,” said Zhang Yong, Chairman of Jiangsu Feng’ao Biotechnology Co., Ltd.
Since the first Jiangsu Development Conference was held in 2017, Taizhou City has seized the opportunity to hold activities such as the Vaccine Innovation Forum, attracting a large amount of investment and helping local enterprises and institutions further expand new space for their going global initiatives.
The Vaccine Engineering Center of China Pharmaceutical City, an important platform for the transformation and incubation of achievements in the vaccine industry, has cooperated with biomedical enterprises in Shanghai, Shandong, Zhejiang and other places through a series of promotion activities, and undertook some international cooperation projects for clinical trials of COVID-19 vaccine, promoting more innovative resources to gather in Taizhou and more innovative achievements to be commercialized and implemented.
“In the next step, we will establish an offshore innovation center and incubator in Beijing, Shanghai, and Guangzhou, which are active in technological innovation, so as to introduce technological innovation projects to serve the development of local industries,” said Peng Fuzhong, Director of Vaccine Engineering Center of China Pharmaceutical City.
The Jiangsu Development Conferences held in 2017 and 2019 have effectively promoted the vigorous development of Taizhou's major health industry. As of 2022, China Pharmaceutical City has gathered more than 1200 domestic and foreign pharmaceutical enterprises, applied for the landing of more than 2100 "world-class and domestically leading" pharmaceutical innovation achievements, and settled more than 4300 high-level talents from home and abroad to start businesses. In 2022, Taizhou recorded a total output value of 170 billion yuan in the health manufacturing industry, accounting for one twentieth of the national total.
